Anti-CD20 Monoclonal Antibodies Market projected to reach $12.94 billion by 2030 at 7.5% CAGR

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Anti-CD20 Monoclonal Antibodies Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The anti-cd20 monoclonal antibodies market size has observed significant growth in recent years. This market is forecast to expand from $9 billion in 2025 to $9.7 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. The historical expansion can be attributed to the approval and widespread adoption of rituximab, an increase in the incidence of non-hodgkin’s lymphoma and chronic lymphocytic leukemia, growing awareness of targeted therapies, the availability of hospital pharmacy distribution channels, and the broader use of intravenous administration routes.

The anti-cd20 monoclonal antibodies market size is projected to experience significant expansion over the coming years. It is anticipated to reach $12.94 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.5%. This growth during the forecast period is propelled by factors such as the development of obinutuzumab and ofatumumab biosimilars, the increasing acceptance of subcutaneous formulations, growing investment in research and academia, the expansion of ambulatory care centers, and an escalating demand for anti-cd20 therapies in numerous autoimmune diseases. Furthermore, key trends in the forecast period encompass a rising adoption of monoclonal antibody therapies for b-cell malignancies, the development of biosimilars and next-generation anti-cd20 antibodies, the expansion of subcutaneous and patient-friendly administration routes, an increasing focus on personalized and targeted immunotherapy, and the growing number of clinical trials and research efforts in autoimmune and oncology indications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp

What Drivers Are Influencing The Anti-CD20 Monoclonal Antibodies Market?

The anticipated expansion of the anti-CD20 monoclonal antibodies market is linked to the increasing prevalence of autoimmune conditions. These conditions arise when the body’s immune system mistakenly attacks its own cells, perceiving them as harmful. A rise in environmental pollutant exposure, capable of disrupting immune regulation and initiating attacks on bodily tissues, contributes to the increase in autoimmune diseases. Anti-CD20 monoclonal antibodies address autoimmune disorders by eradicating B cells, which are responsible for producing autoantibodies and inflammation. These antibodies aid in modulating the immune system’s response and alleviating disease manifestations. For example, data from February 2024 by Arthritis Australia, an Australian non-profit, projects that approximately 562,378 Australians will have RA in 2025, representing 14% of all arthritis cases during that year. This figure is projected to climb by 33% to 748,721 people by 2040. This indicates an additional 186,343 Australians will be affected by RA in 2040 relative to 2025. Consequently, the increasing incidence of autoimmune conditions is a key driver for the expansion of the anti-CD20 monoclonal antibodies market.

What Major Segment Divisions Exist Within The Anti-CD20 Monoclonal Antibodies Market?

The anti-cd20 monoclonal antibodies market covered in this report is segmented –

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications

5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users

Subsegments:

1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux

2) By Obinutuzumab: Gazyva, Biosimilar Candidates

3) By Ofatumumab: Arzerra, Kesimpta

4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

How Are Trends Shaping The Direction Of The Anti-CD20 Monoclonal Antibodies Market?

Leading entities within the anti-CD20 monoclonal antibody market are concentrating on creating enhanced products, including obinutuzumab, to more efficiently combat resistant or relapsed B-cell malignancies. This drug, obinutuzumab, functions as a humanized type II anti-CD20 monoclonal antibody, formulated to pinpoint and eliminate CD20-positive B cells linked to specific blood cancers and autoimmune conditions. An example of this advancement occurred in March 2025, when Roche, a biopharmaceutical firm based in Switzerland, disclosed that the US Food and Drug Administration (FDA) approved a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) for treating lupus nephritis. This acceptance was underpinned by favorable outcomes from the Phase III REGENCY study, which indicated an enhanced complete renal response (CRR) when the drug was used alongside standard therapy, compared to standard therapy by itself. Consequently, Gazyva/Gazyvaro stands as the sole anti-CD20 monoclonal antibody proven to offer such an advantage in lupus nephritis, a severe lupus-induced inflammation capable of resulting in kidney failure.

Which Companies Are Leading Innovation In The Anti-CD20 Monoclonal Antibodies Market?

Major companies operating in the anti-cd20 monoclonal antibodies market are F. Hoffmann-La Roche Ltd., Novartis AG, Biogen Idec, TG Therapeutics, Celltrion Inc., Shanghai Henlius Biotech Inc., Innovent Biologics, Dr. Reddy’s Laboratories Ltd., Genmab A/S, AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Sanofi SA, Bristol-Myers Squibb Company, Samsung Bioepis, Sandoz International GmbH, Amneal Pharmaceuticals LLC, Viatris Inc., Intas Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Biocon Biologics Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Adello Biologics, Mabion SA, mAbxience, Probiomed S.A. de C.V., Prestige Biopharma Ltd., CinnaGen Co., JHL Biotech Inc., Amgen Biologics Pvt. Ltd.

Read the full anti-cd20 monoclonal antibodies market report here:

https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Anti-CD20 Monoclonal Antibodies Market?

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Anti-CD20 Monoclonal Antibodies Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25693&type=smp

Browse Through More Reports Similar to the Global Anti-CD20 Monoclonal Antibodies Market 2026, By The Business Research Company

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Polyclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795